TriangleFOR PATIENTS · SOURCE READING
Treatment of Recurrent Classic Hodgkin Lymphoma
Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 27, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of recurrent classic Hodgkin lymphoma in adults may include:
Source links and citations
Immunotherapy with an immune checkpoint inhibitor (pembrolizumab or nivolumab) with or without combination chemotherapy. This may be followed by stem cell transplant.
Targeted therapy with a monoclonal antibody (brentuximab vedotin) with or without immunotherapy with an immune checkpoint inhibitor (nivolumab).
Source links and citations
Combination chemotherapy with radiation therapy to the areas of the body with cancer for patients older than 60 years.
Radiation therapy with or without chemotherapy, for patients whose cancer came back only in the lymph nodes.
Source links and citations
Immunotherapy as palliative therapy to relieve symptoms and improve quality of life.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice